Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd. - Common Shares
(NQ:
CYTO
)
0.3001
UNCHANGED
Last Price
Updated: 3:55 PM EST, Dec 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.3001
Bid (Size)
0.2800 (2)
Ask (Size)
0.2870 (58)
Prev. Close
0.3001
Today's Range
0.3001 - 0.3001
52wk Range
0.3001 - 0.5750
Shares Outstanding
12,869,587
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
December 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
November 06, 2024
Via
Benzinga
Performance
YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-42.0%
-42.0%
More News
Read More
Altamira Therapeutics Provides Update on Nasdaq Listing
October 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
September 27, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
September 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
September 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
September 19, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
September 17, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
September 16, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
September 03, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
August 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
August 16, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
August 15, 2024
Via
InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
↗
August 15, 2024
Via
Benzinga
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
July 19, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
June 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update
May 28, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Hunting For Gains In Penny Stocks
↗
May 26, 2024
Via
Talk Markets
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
Via
FinancialNewsMedia
Topics
Death
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 23, 2024
Via
Benzinga
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
What's Going On With Altamira Therapeutics Stock?
↗
May 23, 2024
Via
Benzinga
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Frequently Asked Questions
Is Altamira Therapeutics Ltd. - Common Shares publicly traded?
Yes, Altamira Therapeutics Ltd. - Common Shares is publicly traded.
What exchange does Altamira Therapeutics Ltd. - Common Shares trade on?
Altamira Therapeutics Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Altamira Therapeutics Ltd. - Common Shares?
The ticker symbol for Altamira Therapeutics Ltd. - Common Shares is CYTO on the Nasdaq Stock Market
What is the current price of Altamira Therapeutics Ltd. - Common Shares?
The current price of Altamira Therapeutics Ltd. - Common Shares is 0.3001
When was Altamira Therapeutics Ltd. - Common Shares last traded?
The last trade of Altamira Therapeutics Ltd. - Common Shares was at 12/19/24 03:55 PM ET
What is the market capitalization of Altamira Therapeutics Ltd. - Common Shares?
The market capitalization of Altamira Therapeutics Ltd. - Common Shares is 3.86M
How many shares of Altamira Therapeutics Ltd. - Common Shares are outstanding?
Altamira Therapeutics Ltd. - Common Shares has 4M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
